We assessed the impact of constitutive TCF-1B expression on the functions of human CD8+ T-cells also engineered to express a therapeutic TCR specific to NY-ESO-1, a particularly immunogenic and widely expressed cancer-associated-antigen. The gene discussed is CD8A; the disease is cancer.